Slide 1: 9M and Q3 2024 Results
9M and Q3 2024 Results Conference call and webcast for investors and analysts 12 November 2024
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Conference call agenda
9M and Q3 2024 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Dave Fredrickson Susan Galbraith EVP, Oncology Business EVP, Oncology R&D BioPharmaceuticals Ruud Dobber Sharon Barr EVP, BioPharm
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CH I EF E X ECU T IV E OF F I CE R
Slide 5: Strong underlying performance in Q3 and 9M 2024
CEO Opening CEO Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Strong underlying performance in Q3 and 9M 2024 Double-digit Total Revenue and Core EPS growth Double-d
Slide 6: Benefitting from global presence of growing portfolio
CEO Opening CEO Remarks Opening Remarks Financial Results Oncology Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Benefitting from global presence of growing portfolio Double-digit growth across US, EU and EM with broad-based distributi
Slide 7: Multiple high-value Phase III readouts in 2024
CEO Opening CEO Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Multiple high-value Phase III readouts in 2024 LAURA | Stg III u/r NSCLC ADRIATIC | LS-SCLC Expanding T
Slide 8: Financial Results
Financial Results Aradhana Sarin CH I EF FI NANCI AL OFFI CER
Slide 9: Global demand growth across leading medicines
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Global demand growth across leading medicines Top medicines by 9M 2024 Total Revenue BIBP Strong Product
Slide 10: 9M and Q3 2024 – Reported profit and loss
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease 9M and Q3 2024 – Reported profit and loss 9M 2024 CER change % Total Q3 2024 CER change % Total $m % Rev
Slide 11: 9M and Q3 2024 – Core profit and loss
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease 9M and Q3 2024 – Core profit and loss 9M 2024 CER change % Total Q3 2024 CER change % Total $m % Revenue
Slide 12: Upgrading FY 2024 guidance
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Upgrading FY 2024 guidance Net cash inflow from operating activities increased 12% in 9M 2024 Net debt b
Slide 13: Oncology
Oncology Dave Fredrickson ON CO LOG Y B U S IN E S S Susan Galbraith ONCO LOG Y R &D
Slide 14: Oncology – 9M and Q3 2024
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Oncology – 9M and Q3 2024 Total Revenue +22% in 9M 2024 driven by global demand for key medicines Oncology Q3 2024: key dyn
Slide 15: Oncology – R&D highlights
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Oncology – R&D highlights Continuing momentum across Oncology with data at key medical congresses in H2 2024 WCLC and ESMO
Slide 16: Oncology – R&D highlights
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Oncology – R&D highlights Reinforcing leadership in EGFRm NSCLC with novel treatment approaches Tagrisso established backbo
Slide 17: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BI OP H A RM A CEU T IC A LS B U S IN E S S Sharon Barr BI OP H A RM A CEU T IC A LS R &D
Slide 18: BioPharmaceuticals – 9M and Q3 2024
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease BioPharmaceuticals – 9M and Q3 2024 Total Revenue $15.9bn, +20% – strong growth across CVRM, R&I and V&I
Slide 19: BioPharmaceuticals – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – R&D highlights Multiple high potential NMEs and novel combinations to drive next wave of CVRM growth Cardiovascular Renal Metabolism heart failure | hypertension | dyslipidaemia |
Slide 20: BioPharmaceuticals – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – R&D highlights Positive Phase III WAYPOINT trial reinforces Tezspire first-in-class mechanism of action Phase III WAYPOINT trial Multiple Tezspire indication Tezspire met both co-p
Slide 21: Rare Disease
Rare Disease Marc Dunoyer CH I EF E X ECU T IV E OF F I CE R, ALE XI ON
Slide 22: Rare Disease – 9M and Q3 2024
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Rare Disease – 9M and Q3 2024 Total Revenue +14% in 9M 2024 driven by continued neurology growth Rare Di
Slide 23: Rare Disease – R&D highlights
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease Rare Disease – R&D highlights Expanding the potential of Koselugo to adult patients with NF1-PN NF1-PN Phase III KOMET tria
Slide 24: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CH I EF E X ECU T IV E OF F I CE R
Slide 25: Catalyst rich path through 2025, potential to unlock value through 2030
CEOCEO Opening Remarks Opening Remarks Financial Results Oncology Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease AstraZeneca – catalyst rich path through 2025, with potential to unlock significant value through 2030 and beyond Indicatio
Slide 26: On track to deliver on strategic ambitions
CEO Opening CEO Remarks Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEOCEO Closing Remarks Closing Remarks Financial Results Oncology BioPharmaceuticals Rare Disease On track to deliver on strategic ambitions Ambition to deliver $80bn in On track to deliver mid-30s% Am
Slide 27: Q&A Session
Q&A Session Pascal Soriot Aradhana Sarin Marc Dunoyer E XE C UT I V E DI R EC T O R & E XE C UT I V E DI R EC T O R & C HI E F EX E CU T IV E O FF IC E R, C HI E F EX E CU T IV E O FF IC E R C HI E F FI N A N CI A L O F FI C ER A L E XI O N Susan Galbraith Dave Fredrickson Sharon Barr E XE C UT I V
Slide 28: Appendix & Glossary
Appendix & Glossary • Glossary • Oncology tumour maps • Key medicines performance by therapy area
Slide 29: Glossary – abbreviations
G LO S S A R Y Glossary – abbreviations ADC antibody drug conjugate EPS Earnings per share LDL-C low-density lipoprotein cholesterol R&D research and development API active pharmaceutical ingredient ERoW Established rest of world m millions R&I Respiratory and immunology ASCO American society of cli
Slide 30: AstraZeneca in Lung Cancer
A PP END I X | Oncology tumour maps AstraZeneca in Lung Cancer Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 resectable unresectable metastatic Leading the future of Stg. I-III Stg. I-II Stg. III 1L 2L+ lung cancer treatment Est. epi (G7) ~200K ~30K ~70K ~350K ~29
Slide 31: AstraZeneca in Breast Cancer
A PP END I X | Oncology tumour maps AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death established SoC Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7) 540k 125k 90k 65k 55k Enhertu ± THP NST→ residual disease → HER2-positive
Slide 32: Oncology – Tagrisso, Lynparza
A PP END I X | Total Revenue Performance Oncology Tagrisso Lynparza 15% growth at CER to $4,877m in 9M 2024 10% growth at CER to $2,228m in 9M 2024 1,800 1,000 1,600 1,400 800 1,200 Total Revenue ($m) Total Revenue ($m) 600 1,000 800 400 600 400 200 200 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3
Slide 33: Oncology – Imfinzi, Imjudo
A PP END I X | Total Revenue Performance Oncology Imfinzi Imjudo 22% growth at CER to $3,463m in 9M 2024 32% growth at CER to $208m in 9M 2024 1,400 80 70 1,200 60 1,000 Total Revenue ($m) 50 Total Revenue ($m) 800 40 600 30 400 20 200 10 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 202
Slide 34: Oncology – Calquence, Enhertu
A PP END I X | Total Revenue Performance Oncology Calquence Enhertu 27% growth at CER to $2,321m in 9M 2024 60% growth at CER to $1,442m in 9M 2024 900 600 800 500 700 600 400 Total Revenue ($m) Total Revenue ($m) 500 300 400 300 200 200 100 100 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 35: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
A PP END I X | Total Revenue Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 34% growth at CER to $5,779m in 9M 2024 1% growth at CER to $992m in 9M 2024 34% growth at CER to $392m in 9M 2024 2,500 400 160 350 140 2,000 300 120 Total Revenue ($m) Total Rev
Slide 36: BioPharmaceuticals: Respiratory & Immunology
A PP END I X | Total Revenue Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Breztri Tezspire 8% growth at CER to $1,218m in 9M 2024 53% growth at CER to $721m in 9M 2024 >2x growth at CER to $471m in 9M 2024 500 300 250 450 250 400 200 350 200 Total Revenue ($m) Total Revenue ($m)
Slide 37: BioPharmaceuticals: Respiratory & Immunology
A PP END I X | Total Revenue Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Pulmicort 22% growth at CER to $2,195m in 9M 2024 9% growth at CER to $517m in 9M 2024 900 250 800 700 200 600 Total Revenue ($m) Total Revenue ($m) 150 500 400 100 300 200 50 100 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 38: Rare Disease
A PP END I X | Total Revenue Performance Rare Disease Ultomiris Soliris Strensiq 35% growth at CER to $2,835m in 9M 2024 11% decrease at CER to $2,045m in 9M 2024 19% growth at CER to $996m in 9M 2024 1,200 1,000 400 900 350 1,000 800 300 700 800 Total Revenue ($m) Total Revenue ($m) Total Revenue (